UNISON Clinical Trials (Shahram Jacobs md inc.)
Welcome,         Profile    Billing    Logout  
 0 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stough, Dowling B
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
HZNP-DAX-201, NCT05368103: Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

Completed
2
30
Canada, US
Daxdilimab, HZN-7734
Amgen
Alopecia Areata
08/23
01/24
Petersen, Dena
NCT04209543 / 2019-001289-14: Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Completed
3
1570
Europe, Canada, US, RoW
Estetrol, Placebo, Progesterone
Estetra, ICON Clinical Research
Vasomotor Symptoms, Menopausal Symptoms
02/24
02/24
NCT05264506: Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

Terminated
3
2007
US
NOMAC-E2 COC, Nomegestrol acetate / estradiol
Organon and Co, IQVIA Inc., OSTAtistics
Contraception
01/24
01/24
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
BRISOTE, NCT06750289: Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

Not yet recruiting
3
400
US
ICS-LABA, benralizumab, Placebo for Benralizumab
AstraZeneca
Eosinophilic Asthma
10/27
10/27
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Active, not recruiting
2
285
US
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
01/25
02/25
ZUPREME-1, NCT06662539: Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

Recruiting
2
480
Europe, US
Petrelintide, ZP8396, Placebo
Zealand Pharma, Parexel
Obesity
11/25
04/26
TRANSFORM, NCT06112418: A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

Recruiting
N/A
7500
US
The Cleerly CAD Staging System
Cleerly, Inc., CPC Clinical Research
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
03/29
03/29
Hamann, Dathan
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting
3
693
Europe, Canada, Japan, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
08/25
04/26
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
2
350
Europe, Canada, US, RoW
Eltrekibart, LY3041658, Placebo
Eli Lilly and Company
Hidradenitis Suppurativa
08/25
07/26

Download Options